Annovis Bio Stock Surges on Promising Parkinson’s Trial Results

Annovis Bio US03615A1088

Annovis Bio shares experienced a dramatic upward move following the release of encouraging clinical trial data for its Parkinson’s disease treatment, Buntanetap. The biotechnology firm’s stock surged as much as 56% during Monday’s trading session, propelled by groundbreaking study outcomes and a massive increase in trading activity.

The company maintains a solid financial foundation with $15.3 million in cash and equivalents, providing operational funding through the third quarter of 2026. Recent quarterly figures reveal the company’s current financial performance:

• Research and development expenditures: $6.3 million
• General and administrative costs: $1.1 million
• Loss per share: $0.37